AzTrials
AzTrials

Acute Kidney InjuryWeCANNCT06214390

Urinary Parameters to Predict Weaning of Renal Replacement Therapy in the Critically Ill

A study testing Single strategy and Combined strategy in people with Acute Kidney Injury, run by University Hospital, Montpellier at 2 sites in France.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Data on the optimal period for RRT weaning in critically ill patient are scarce. The current practice for RRT weaning is based on urine output, the threshold of which is debatable. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Acute Kidney Injury
What is being tested?
Single strategy and Combined strategy
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
600 participants
Where
2 sitesFrance
Study dates
Jan 2024to Dec 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Adults (18 years of age or older)
  • Admitted to the ICU
  • Receiving or having received invasive mechanical ventilation and/or catecholamine infusion (epinephrine or norepinephrine or dobutamine) at least 48h
  • With acute kidney injury, at KDIGO 3 (See Appendix 1) stage and associated with oliguria at least < 200ml/ 24h before RRT initiation
  • Treated with intermittent or continuous renal replacement therapy
  • Resumption of urine output > 300ml/24h with or without diuretic use

Who cannot join

  • Preexisting Chronic kidney disease with estimated glomerular filtration rate (eGFR) < 30ml/min
  • AKI caused by vascular occlusion, glomerulonephritis, vasculitis, post-renal obstruction, thrombotic microangiopathy, tumor lysis syndrome
  • RRT for another cause than AKI (eg: drug intoxication,...)
  • Decision to forgo life-sustaining treatment including RRT
  • Cirrhosis with Child-Pugh score of C or hepatorenal syndrome
  • Kidney transplantation
Show all 12Show fewer
  • Patient already enrolled in the study
  • Participation in another clinical trial assessing the impact or duration of RRT
  • Pregnancy in progress or planned during the study period or breastfeeding women
  • Patients protected by law (Art. L1121-6 and L1121-8 of the Code de la Santé Publique) : Adult protected by law or patient under guardianship or curatorship
  • Subjects not covered by public health insurance
  • Absence of written informed consent from the patient or his or her proxy (if present) before inclusion or when possible when the patient has been included in an emergency setting

Trial locations and contacts

2 sites in 1 country.

France2 sites
  • Clermont-Ferrand Hospital University

    Clermont-Ferrand

    Alexandre LAUTRETTE, alautrette@chu-clermontferrand.fr

  • Montpellier University Hospital

    Montpellier, 34295

    Kada KLOUCHE, 0467338441 ext. +33, k-klouche@chu-montpellier.fr

Other trials in France

About this study

Official title: Weaning of Renal Replacement Therapy in Critically Ill Patients With Acute Kidney Injury: Predictive Performance of Urinary Parameters

Data on the optimal period for RRT weaning in critically ill patient are scarce. The current practice for RRT weaning is based on urine output, the threshold of which is debatable. Two recent observational studies have shown that an increase in urinary creatinine or urea concentrations is a better predictive marker of RRT weaning than urine output.

An unjustified delay in RRT weaning leads to numerous complications such as catheter-related infections, delay of the patient's functional recovery, severe ionic disorder, bleeding, and induced hemodynamic instability. It also induces an increase workload for careers and in cost without any additional benefit for the patient. Conversely, too early weaning inevitably limits the prevention on fluid accumulation that is independently associated with an increased risk of mortality and inevitably leads to resumption of RRT requiring reinsertion of dialysis catheter resulting in potential complications.

Read more

A multicentre randomized controlled trial will be then necessary and only able to identify the optimal RRT weaning strategy.

The main objective is to compare two RRT weaning strategies on RRT duration in critically ill patients with acute kidney injury: a strategy based on combined criteria (urine output + urinary parameters) as compared to a single strategy based only on urine output.

The study protocol will be an open-label, two parallel group, multicenter, randomized, controlled clinical trial, in which enrolled ICU adult patients will have RRT weaning based either on urine output alone (single strategy) or on urine output and urinary parameters (combined strategy).

When the urine output is greater than 500ml/24h, the enrollment must be performed within 24hours in 2 groups:.

" Single strategy ": In the single strategy, RRT weaning will be achieved when urine output exceeds 500ml/24h without diuretics or 2000ml/24h with diuretics use.

" Combined strategy": In the combined strategy, when urine output exceeds 500ml/day with or without diuretic use, RRT will be stopped during 48h to assess urinary indices (urinary creatinine and urea). Soon as urinary indices are higher than thresholds values (urinary creatinine > 5.2mmol/day and urinary urea > 1.35mmol/kg/day, RRT will be weaned. If they are lower, a RRT session will be perform after which the weaning process will be resume.

The primary endpoint is the number of RRT-free days at D30 with at least 7 consecutive days alive and without RRT.

Read the detailed description

RRT is an invasive high-cost treatment with potentially severe complications. However, there is a major dearth of data on RRT weaning in the ICU. The weaning strategy using only urine output is based on scarce and debatable data. The two observational studies concluded independently that the urinary concentration of creatinine or urea would be able to predict RRT weaning. These new data propose a novel combined strategy based on urine output and urinary parameters which are more specific to renal recovery and potentially better suited to determine the optimal period of RRT weaning.

This trial aims to determine the best RRT weaning strategy and so indirectly to determine the optimal duration of RRT in the ICU. Our trial methodology is able to determine clearly if one of the two weaning strategies is more effective and will lead to more health benefits and fewer risks for ICU patients.It is an open-label, two parallel group, multicenter, randomized, controlled clinical trial, in which enrolled ICU adult patients will have RRT weaning based either on urine output alone (single strategy) or on urine output and urinary parameters (combined strategy).

Critically ill patients aged 18 and over, admitted to the ICU, receiving or having received invasive mechanical ventilation and/or catecholamine infusion at least 48h, with acute kidney injury, at KDIGO 3 stage associated with oliguria at least < 200ml/ 24h before RRT initiation, treated with intermittent or continuous renal replacement therapy and resumption of urine output > 300ml/24h with or without diuretic use; will be included in the study.

Enrolled patients will be randomized into two groups, the single strategy or the combined strategy. When the urine output is greater than 500ml/24h, the enrollment must be performed within 24hours:

"Single strategy": RRT weaning will be achieved when urine output exceeds 500ml/24h without diuretics or 2000ml/24h with diuretics use.

"Combined strategy": When urine output exceeds 500ml/day with or without diuretic use, RRT will be stopped during 48h to assess urinary indices (urinary creatinine and urea). Soon as urinary indices are higher than thresholds values (urinary creatinine > 5.2mmol/day and urinary urea > 1.35mmol/kg/day), RRT will be weaned. If they are lower, a RRT session will be perform after which the weaning process will be resume.

After the RRT weaning, RRT will be resumed both groups if there is at least one of the following criteria:

  • oliguria (urine outpout <300ml/24h with or without diuretic use) or anuria >72h;
  • serum urea concentration >40mmol/L,
  • serum potassium concentration of more than 5.5mmol/L despite medical treatment
  • pH <7.15 in a context of pure metabolic acidosis (PaCO2 <35 mmHg) or in a context of mixed acidosis with PaCO2 ≥50mmHg without possibility of increasing alveolar ventilation and despite medical treatment;
  • Acute pulmonary edema due to fluid overload responsible for severe hypoxemia requiring oxygen flow rate >5 l/min to maintain a SpO2 ≥ 95% or requiring an FiO2 >50% in patients on high-flow cannula oxygen therapy or invasive or non-invasive mechanical ventilation and despite diuretic therapy (equivalent to furosemide dose of 1mg/kg at least).

If several weaning are performed because RRT is resumed many times during the ICU stay, the patient will keep the assigned weaning strategy at randomization to D30.

The days elapsed between two RRT sessions are not considered as RRT-weaned days if they are less than 7 consecutive days, and are not taken into account.

The primary endpoint is the number of RRT-free days at D30 with at least 7 consecutive days alive and without RRT.

To highlight a minimal clinically difference of 2 RRT-weaned days between groups for a two-sided type I error at 5% and a statistical power greater than 90% [55], we have estimated that 600 patients (300 by group) will be necessary, with 1) variability (standard-deviation and interquartile range) of RRT-free days ranged between (median [interquartile range]) 17 [2-26] vs. 19 [5-29] , and 12 [1; 25] vs. 16 [2; 28] and 2) 30-day mortality around 35 to 45%.

The choice of the difference of 2 RRT-weaned days was determined according to clinical relevance corresponding to a reduction of at least one RRT session.

To compare two RRT weaning strategies on its duration in patients: a strategy based on combined criteria (urine output + urinary parameters) as compared to a single strategy based only on urine output, the primary analysis will be performed by Student t-test or the nonparametric Mann-Whitney if the assumptions of the t-test are not met. The homoscedasticity will be analyzed using Fisher-Snedecor test. Results will be expressed as effect-size and 95% confidence interval.

Being tested
Single strategy, Combined strategy
Keywords
Renal Replacement Therapy, Urine Ouput, Weaning, Critical care, urinary biomarkers
Medical subject headings
Acute Kidney Injury

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Single strategyProcedure or surgery

    In the single strategy, RRT weaning will be achieved when urine output exceeds 500ml/24h without diuretics or 2000ml/24h with diuretics use

  • Combined strategyProcedure or surgery

    In the combined strategy, when urine output exceeds 500ml/day with or without diuretic use, RRT will be stopped during 48h to assess urinary indices (urinary creatinine and urea). Soon as urinary indices are higher than thresholds values (urinary creatinine > 5.2mmol/day [5] and 3) urinary urea > 1.35mmol/kg/day (using the patient's body weight at ICU admission) [6], RRT will be weaned. If they are lower, a RRT session will be perform after which the weaning process will be resume.

Study groups in NCT06214390
Study groupRoleWhat they receive
Single strategyActive comparatorA single strategy based only on urine output
Receives: Procedure: Single strategy
Combined strategyExperimentalA strategy based on combined criteria (urine output + urinary parameters)
Receives: Procedure: Combined strategy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of RRT-free days at D30 with at least 7 consecutive days alive and without RRT

    Days without RRT

    Measured: Day30

Secondary outcomes (26)
  1. Number of RRT weaned days at Day90

    Days without RRT

    Measured: Day90

  2. Number of RRT sessions in ICU and at Day90

    Days without RRT

    Measured: in ICU and at Day90

  3. Renal recovery at Day30

    Number of patient with a serum creatinine lower than 125% of the baseline serum creatinine

    Measured: Day30

  4. Renal recovery at Day90

    Number of patient with a serum creatinine lower than 125% of the baseline serum creatinine

    Measured: Day90

  5. Serum Creatinine and urea at ICU discharge

    Serum creatinine and urea values

    Measured: Day of ICU discharge

  6. Serum Creatinine and urea at Day90

    Serum creatinine and urea values

    Measured: Day90

  7. Number of days in ICU and hospital within Day90

    Days

    Measured: within Day90

  8. Rate of ICU, hospital and Day90 mortality

    Number of died patients

    Measured: Day90

  9. Costs related to RRT and ICU stay within Day90

    Euros

    Measured: within Day90

  10. Number of RRT resumption between inclusion and Day30

    Number of RRT

    Measured: between inclusion and Day30

  11. Rate of dialysis catheter-related colonization in ICU

    Number per patient and number per catherter-days

    Measured: Day30

  12. Rate of dialysis catheter-related infection in ICU

    Number per patient and number per catherter-days

    Measured: Day30

  13. Incidence of hypokalemia with and without clinical complications in ICU

    Defined as a serum potassium concentration < 3.5 mmol/L

    Measured: Day30

  14. Incidence of hypophosphatemia with and without clinical complications in ICU

    Defined as a serum phosphate concentration < 0.6 mmol/L

    Measured: Day30

  15. Incidence of hyponatremia with and without clinical complications in ICU

    Defined as a serum sodium concentration < 135 mmol/L

    Measured: Day30

  16. Rate of bleeding and etiologies in ICU

    Number per patient

    Measured: Day30

  17. Rate of cardio-vascular events in ICU

    Defined as : rhythm disorders (ventricular tachycardia, ventricular fibrillation, episode of atrial fibrillation requiring medical treatment or external electric counter shock), cardiac failure, ischemic events, cardiac arrest, arterial hypotension and hypertension requiring treatment

    Measured: Day30

  18. Rate of severe hypoxemia related to fluid overload

    Defined as pulmonary edema requiring oxygen therapy to maintain an SpO2 of more than 95% in ICU

    Measured: Day30

  19. Rate of documented gastric ulcers in ICU

    Number per patient

    Measured: Day30

  20. Rate of nosocomial infections in ICU

    Number per patient

    Measured: Day30

  21. Nadir of serum bicarbonate in ICU

    Serum bicarbonate value

    Measured: Day30

  22. Number of days with mechanical ventilation and high-flow nasal cannula oxygen therapy in ICU

    Days

    Measured: Day30

  23. Number of days with vasopressors treatment in ICU

    Days

    Measured: Day30

  24. Incidence of hyperkalemia with and without clinical complications in ICU

    Defined as a serum potassium concentration > 5 mmol/L

    Measured: Day30

  25. Incidence of hyperphosphatemia with and without clinical complications in ICU

    Defined as a serum phosphate concentration > 1.5 mmol/L

    Measured: Day30

  26. Incidence of hypernatremia with and without clinical complications in ICU

    Defined as a serum sodium concentration > 145 mmol/L

    Measured: Day30

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Jan 2024
  2. Study startJan 2024 (estimated)
  3. Primary completionSep 2025 (estimated)
  4. Study completionDec 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
600 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06214390
Sponsor's protocol ID
RECHMPL21_0530
Acronym
WeCAN
Status last verified
Jan 2024
First submitted
21 Dec 2023
Last updated
19 Jan 2024
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Single strategy and Combined strategy in people with Acute Kidney Injury, run by University Hospital, Montpellier at 2 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 19 Jan 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Kada KLOUCHE (0467338441, k-klouche@chu-montpellier.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of RRT-free days at D30 with at least 7 consecutive days alive and without RRT (time frame: Day30). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Jan 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in